Cybin Inc. (NYSE:CYBN - Free Report) - Equities researchers at HC Wainwright dropped their FY2029 earnings estimates for Cybin in a note issued to investors on Wednesday, July 31st. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.25 for the year, down from their prior estimate of $0.26. HC Wainwright has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Cybin's current full-year earnings is ($0.09) per share.
Cybin (NYSE:CYBN - Get Free Report) last released its quarterly earnings results on Wednesday, June 26th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02).
Separately, Cantor Fitzgerald reissued an "overweight" rating on shares of Cybin in a report on Wednesday.
View Our Latest Analysis on CYBN
Cybin Stock Performance
Shares of Cybin stock traded down $0.01 during trading on Friday, reaching $0.27. The company's stock had a trading volume of 3,471,546 shares, compared to its average volume of 4,709,471. The company has a market capitalization of $110.93 million, a price-to-earnings ratio of -1.36 and a beta of 0.43. The stock has a 50-day moving average price of $0.29. Cybin has a fifty-two week low of $0.25 and a fifty-two week high of $0.74.
Hedge Funds Weigh In On Cybin
A number of large investors have recently bought and sold shares of CYBN. PEAK6 Investments LLC purchased a new stake in shares of Cybin in the first quarter valued at approximately $95,000. AWM Investment Company Inc. acquired a new stake in Cybin in the first quarter valued at $930,000. Rosalind Advisors Inc. lifted its holdings in Cybin by 38.3% in the second quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company's stock valued at $5,230,000 after acquiring an additional 5,340,000 shares during the period. Ikarian Capital LLC purchased a new stake in shares of Cybin during the 1st quarter worth $5,770,000. Finally, RA Capital Management L.P. acquired a new position in shares of Cybin during the 1st quarter worth $24,041,000. Hedge funds and other institutional investors own 17.94% of the company's stock.
Cybin Company Profile
(
Get Free Report)
Cybin Inc is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc is based in Toronto, Canada.
See Also
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
